| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dengue (DENV) virus strains for each of the four DENV serotypes were modified by passage in primary dog kidney (PDK) cell cultures with final manufacture of vaccine lots in fetal rhesus monkey diploid cell cultures. "Strain sets" consisting of serially-passaged DENV were inoculated in rhesus monkeys along with unmodified parent viruses for each strain. Vaccine candidates were compared with unmodified parent viruses by measuring viremia and immune responses. All except one DENV-1 strain demonstrated reduced infection in monkeys after PDK cell passage. A DENV-3 strain lost all monkey infectivity after PDK cell passage. Twelve vaccine candidates were selected for Phase 1 human trials through this selection process.
Authors’ addresses: Kenneth H. Eckels, Robert Putnak, David W. Vaughn, Medical Infections Diseases Research Program, U.S. Army Medical Research and Material Command, Ft. Detrick, Frederick, MD 21702-5012, Division of Communicable Diseases and Immunology, Walter Reed Army Institute of Research, Silver Spring, MD 20910. Doria R. Dubois, Vaccine Research Center, Building 40, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892. Bruce L. Innis, GlaxoSmithKline, 1250 South Collegeville Road, Mail Code UP4330, Collegeville, PA 19426-0989. Erik A. Henchal, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick MD 21702-5011. Charles H. Hoke, Anteon Corp., Medical Systems Program, U.S. Army Medical Research and Material Command, Ft. Detrick, Frederick, MD 21702-5012.
This article has been cited by other articles:
|
|
 |
|
  G. Anez, R. Men, K. H. Eckels, and C.-J. Lai Passage of Dengue Virus Type 4 Vaccine Candidates in Fetal Rhesus Lung Cells Selects Heparin-Sensitive Variants That Result in Loss of Infectivity and Immunogenicity in Rhesus Macaques J. Virol., October 15, 2009; 83(20): 10384 - 10394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Guy, V. Barban, N. Mantel, M. Aguirre, S. Gulia, J. Pontvianne, T.-M. Jourdier, L. Ramirez, V. Gregoire, C. Charnay, et al. Evaluation of Interferences between Dengue Vaccine Serotypes in a Monkey Model Am J Trop Med Hyg, February 1, 2009; 80(2): 302 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Simasathien, S. J. Thomas, V. Watanaveeradej, A. Nisalak, C. Barberousse, B. L. Innis, W. Sun, J. R. Putnak, K. H. Eckels, Y. Hutagalung, et al. Safety and Immunogenicity of a Tetravalent Live-attenuated Dengue Vaccine in Flavivirus Naive Children Am J Trop Med Hyg, March 1, 2008; 78(3): 426 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Sariol, J. L. Munoz-Jordan, K. Abel, L. C. Rosado, P. Pantoja, L. Giavedoni, I. V. Rodriguez, L. J. White, M. Martinez, T. Arana, et al. Transcriptional Activation of Interferon-Stimulated Genes but Not of Cytokine Genes after Primary Infection of Rhesus Macaques with Dengue Virus Type 1 Clin. Vaccine Immunol., June 1, 2007; 14(6): 756 - 766. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Ajariyakhajorn, M. P. Mammen Jr., T. P. Endy, M. Gettayacamin, A. Nisalak, S. Nimmannitya, and D. H. Libraty Randomized, Placebo-Controlled Trial of Nonpegylated and Pegylated Forms of Recombinant Human Alpha Interferon 2a for Suppression of Dengue Virus Viremia in Rhesus Monkeys Antimicrob. Agents Chemother., November 1, 2005; 49(11): 4508 - 4514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. BLANEY JR., C. T. HANSON, C.-Y. FIRESTONE, K. A. HANLEY, B. R. MURPHY, and S. S. WHITEHEAD GENETICALLY MODIFIED, LIVE ATTENUATED DENGUE VIRUS TYPE 3 VACCINE CANDIDATES Am J Trop Med Hyg, December 1, 2004; 71(6): 811 - 821. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
ERRATA Am J Trop Med Hyg, March 1, 2004; 70(3): 336 - 337. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
